Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Financing Activities (2016 - 2025)

Aptevo Therapeutics' Cash from Financing Activities history spans 11 years, with the latest figure at $18.3 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 273.58% year-over-year to $18.3 million; the TTM value through Sep 2025 reached $39.4 million, up 230.7%, while the annual FY2024 figure was $15.6 million, 160.0% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $18.3 million at Aptevo Therapeutics, up from $14.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $23.9 million in Q1 2021 and bottomed at -$4.9 million in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $3.5 million (2023), against an average of $4.3 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 138.22% in 2022 before it soared 968.8% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$3.1 million in 2021, then soared by 294.99% to $6.0 million in 2022, then crashed by 49.22% to $3.0 million in 2023, then skyrocketed by 120.62% to $6.7 million in 2024, then skyrocketed by 172.9% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Cash from Financing Activities are $18.3 million (Q3 2025), $14.4 million (Q2 2025), and $6.7 million (Q4 2024).